On November 16, Dianthus Therapeutics Inc. fell 6.74% in Pre-Market Trading, trading at $95.0 per share, with turnover of $18,000.
The clearest catalyst was a newly disclosed insider transaction: Executive Vice President, CFO and CBO Ryan Savitz sold 124,042 common shares from November 9 to November 12 for about $11.23 million.
The filing indicated the shares sold matched 124,042 shares acquired through option exercises over the same period. After the transactions, he no longer directly held common stock, while retaining 176,884 stock options. The move appears to be the most direct trigger behind the latest pre-market weakness, although the company had previously highlighted a strong cash position of $1.2 billion as of June 30 and said its runway should extend into 2030, while Phase 3 EMERGE results for claseprubart in gMG are expected in the second half of 2028.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)